metaPreg - Oxcarbazepine (Epilepsy) during pregnancy

Oxcarbazepine (Epilepsy) updated on 04-22-2025

Table Graphic exposition period:

Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Congenital malformations
All congenital malformations (majors, minors, majors and minors, or unspecified)	1.46 [1.03, 2.07]	15%	15 studies	148,335	2,306	low	ROB	2.28 [1.20; .]
Major congenital malformations	1.49 [1.03, 2.16]	20%	13 studies	148,308	2,203	probable	ROB	2.35 [1.20; .]
Congenital heart defects	1.93 [0.87, 4.24]	0%	4 studies	42	510	not evaluable	ROB	-
Limb defects	2.81 [0.46, 17.19]	22%	3 studies	12	177	not evaluable	ROB	-
Spina bifida	13.65 [1.72, 108.21]	0%	3 studies	3	152	not evaluable	ROB	26.79 [2.84; .]
Urinary malformations	0.92 [0.20, 4.14]	0%	3 studies	16	503	not evaluable	ROB	-
Digestive system anomalies	5.01 [0.55, 45.94]	0%	2 studies	4	78	not evaluable	ROB	-
Cleft lip with or without cleft palate	5.45 [0.36, 83.53]	15%	2 studies	2	101	not evaluable	ROB	-
Hypospadias	2.04 [0.16, 25.25]	32%	2 studies	12	340	not evaluable	ROB	-
Neural Tube Defects	8.87 [0.71, 110.59]	17%	2 studies	2	340	not evaluable	ROB	-
Oro-facial clefts	6.85 [0.59, 80.08]	37%	2 studies	5	340	not evaluable	ROB	-
Polydactyly	26.41 [2.05, 340.38]	0%	2 studies	1	335	not evaluable	ROB	52.32 [3.52; .]
7 non statistically significant endpoints reported in only one study
Growth parameters and prematurity
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Preterm (< 37 weeks)	1.16 [0.88, 1.53]	0%	4 studies	91,375	674	not evaluable	ROB	-
Small for gestational age (weight)	1.37 [0.99, 1.89]	31%	4 studies	170,029	1,609	not evaluable	ROB	-
Large for gestational age (weight)	0.78 [0.26, 2.30]	10%	2 studies	86	531	not evaluable	ROB	-
Low birth weight (< 2500g)	1.24 [0.94, 1.62]	4%	2 studies	92,544	1,605	not evaluable	ROB	-
3 non statistically significant endpoints reported in only one study
Maternal consequences
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Preeclampsia	1.61 [0.75, 3.47]	0%	2 studies		4	not evaluable	ROB	-
Maternal consequences (as a whole)	1.53 [1.08, 2.17]	-	1 study	712	1,439	not evaluable	ROB	2.43 [1.37; .]
4 non statistically significant endpoints reported in only one study
Neonatal disorders
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Neonatal medical care	3.13 [0.43, 22.52]	63%	3 studies	2,025	471	not evaluable	ROB	-
3 non statistically significant endpoints reported in only one study
Long term consequences
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Child/Infant death (> 28 days of life)	1.87 [0.52, 6.65]	0%	2 studies	4,704	670	not evaluable	ROB	-
Intrauterine deaths
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Intrauterine deaths (as a whole or unspecified)	4.29 [0.62, 29.59]	78%	3 studies	183	332	not evaluable	ROB	-
Late intrauterine deaths (> 22 weeks) / Stillbirths	2.79 [0.68, 11.38]	0%	3 studies	8	269	not evaluable	ROB	-
Perinatal death	2.56 [0.96, 6.84]	0%	2 studies	20	772	not evaluable	ROB	-
2 non statistically significant endpoints reported in only one study
Neuro-developmental disorders
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
ASD (Autism spectrum disorder): Diagnosis/Risk	1.24 [0.82, 1.87]	0%	3 studies	4,662	1,607	not evaluable	ROB	-
Language disorders/delay	2.52 [0.94, 6.73]	70%	3 studies	72,025	166	not evaluable	ROB	-
ASD (Autism spectrum disorder): Diagnosis	1.24 [0.82, 1.87]	0%	2 studies	4,635	1,603	not evaluable	ROB	-
Neuro-developmental disorders (as a whole)	0.96 [0.68, 1.36]	0%	2 studies	10,011	1,572	not evaluable	ROB	-
Cognitive developmental disorders/delay (< 3 years old)	1.71 [0.18, 16.19]	90%	2 studies		52	not evaluable	ROB	-
Psychomotor developmental disorders/delay	1.24 [0.51, 3.06]	47%	2 studies		52	not evaluable	ROB	-
7 non statistically significant endpoints reported in only one study